[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625657":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":27,"locations":32,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":19,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CL-NK-003","EXPERIMENTAL","Fixed-dose for at least 6 patients",[13],"Biological: CL-NK-003",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Fixed-dose (3 × 10\\^9 cells)",[9],null,[21,24],{"name":22,"affiliation":5,"role":23},"Zhuan Liao","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":26,"role":23},"Xuetao Cao","National Key Laboratory of Immunity & Inflammation",[28],{"name":25,"role":29,"phone":30,"phoneExt":19,"email":31},"CONTACT","+86-13124828854","caoxt@immunol.org",[33],{"facility":5,"status":34,"city":35,"state":19,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Shanghai","200433","China","CN",{"type":40,"coordinates":41},"Point",[42,43],121.45806,31.22222,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":30,"phoneExt":19,"email":48},"Yanfang Liu","liuyanfang00215@163.com",{"type":23,"investigatorFullName":22,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Prof.",[52],{"name":53,"class":54},"National Key Laboratory of Immunity and Inflammation","UNKNOWN","100625657","phase-1-car-nk-cells-cl-nk-003-in-pancreatic-cancer-100625657",false,"NCT07425483","CAR-NK Cells (CL-NK-003) in Pancreatic Cancer","A Clinical Study of CAR-NK Cells (CL-NK-003) in Patients With Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* 1\\. Aged 18-75 years;2. Locally advanced, metastatic, or recurrent pancreatic cancer, with immunohistochemical detection of eGR1 (membrane positive tumor cell rate \\>40% and expression intensity ≥2+), who have failed, been intolerant to or reject standard treatment;3. At least 1 measurable lesion according to RECIST 1.1;4. Have not received anti-tumor treatment for at least 4 weeks;5. ECOG performance status of 0-2;6. Estimated life expectancy more than 12 weeks;7. Hematology: neutrophils ≥ 1.5×10\\^9\u002FL, lymphocytes ≥ 0.8×10\\^9\u002FL, hemoglobin ≥ 100 g\u002FL, and platelets ≥ 75 × 10\\^9\u002FL;8. Blood biochemistry: total bilirubin ≤ 2×ULN, alanine aminotransferase ≤ 3×ULN, aspartate aminotransferase ≤ 3×ULN, and creatinine clearance ≥ LLN (Cockcroft-Gault formula);9. Volunteer to participate in this clinical study and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Evidence of central nervous system involvement;2. Have received adoptive cell therapy;3. Patients with any uncontrolled active infection, including but not limited to: HBV, HCV, HIV, or treponema pallidum serology positive;4. Vaccinated with a live attenuated vaccine within 3 months;5. History of immunodeficiency;6. Active autoimmune disease;7. Regular use of systemic corticosteroids within 2 weeks prior to screening at a dose exceeding prednisone 10 mg\u002Fday (or equivalent) on any day; 8. Have severe conditions, including but not limited to: (1) severe respiratory diseases; (2) severe cardiovascular diseases (previous history of CABG\u002FPCI; myocardial infarction\u002Funstable angina pectoris, congestive heart failure of NYHA III-IV, left ventricular ejection fraction \\\u003C 50%, or poorly controlled hypertension within 6 months; QTc interval \\> 480ms, long or short QT syndrome; previous history of ventrical arrhythmia, or ventrical arrhythmia under anti-arrhythmic drugs\u002FICD); (3) poorly controlled diabetes and other metabolic diseases; (4) severe gastrointestinal diseases (severe gastrointestinal bleeding, severe diarrhea of CTCAE ≥ 2, or severe gastrointestinal obstruction needing intervention);9. Possible severe adverse events, allergy or other contraindications to drugs or its component under study;10. Pregnant or lactating women;11. History of neurological or psychological disorders;12. Not suitable to participate this clinical study judged by the investigator.","ALL","18 Years","75 Years",{"count":66,"type":67},9,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","This is a single-center, open-label, first-in-human, fixed-dose study in patients with pancreatic cancer.",[73],"Pancreatic Cancer",[75,76],"pancreatic cancer","CAR-NK","2026-02-13",{"date":79,"type":80},"2026-02-23","ACTUAL",{"date":82,"type":80},"2026-02-12",{"date":84,"type":67},"2028-12",{"name":5,"class":6},1]